OncoMatch/Clinical Trials/NCT05333250
Modafinil to Improve Fatiguability
Is NCT05333250 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Modafinil for cancer-related cognitive difficulties.
Treatment: Modafinil — Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Currently receiving or have received cytotoxic chemotherapy in the last 6 weeks
Cannot have received: blood transfusion
Blood transfusion in the last 2 weeks
Lab requirements
Blood counts
Hemoglobin lower than 80 g/L measured in the last 4 weeks
Liver function
Severe liver dysfunction (total bilirubin >3x upper limit of normal, or aspartate aminotransferase or alanine aminotransferase >5x upper limit of normal)
Cardiac function
Uncontrolled hypertension as defined by a blood pressure greater than 140/90mmHg; Unstable angina; Recent (<6 months previous) myocardial infarction; Evidence of left ventricular hypertrophy or ischemia on ECG; Arrythmia (e.g., atrial fibrillation); Coronary artery disease with Canadian Cardiovascular Society Symptoms Class >1
Hemoglobin lower than 80 g/L measured in the last 4 weeks; Severe liver dysfunction (total bilirubin >3x upper limit of normal, or aspartate aminotransferase or alanine aminotransferase >5x upper limit of normal); Uncontrolled hypertension as defined by a blood pressure greater than 140/90mmHg; Unstable angina; Recent (<6 months previous) myocardial infarction; Evidence of left ventricular hypertrophy or ischemia on ECG; Arrythmia (e.g., atrial fibrillation); Coronary artery disease with Canadian Cardiovascular Society Symptoms Class >1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify